Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Treatment of Testicular Cancer

Treatment of Testicular Cancer Donald 1 Twito. MD. and B. J. Kennedy. MD. Section of Medical Oncology, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455 Carcinoma of the testis is one of the most common forms of lethal malignancy encountered in males IS to 40 years of age (Table 1). The average annual age­ adjusted incidence rate for all races is 3.1 per 100,000 males (1). Although occurring at all ages, it ranks first in incidence rate in males 20 to 34 years of age and accounts for 11.4% of all cancer deaths in the 25-34 age group (2). Approximately 1 % of all malignant tumors in males originate in the testis, accounting for 0.6% of all fatal tumors in males (2). The probability at birth of developing cancer of the testis is 0.16% compared to 5.5% for female breast cancer and 2.5% for lung cancer (2). It is nearly three times more common in whites than non-whites. Cancer of the testis has a significant impact on the social, economic, and emo­ tional status of this young population. There is no doubt that the prevalence of this type of cancer has been underemphasized and the public uninformed. The http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annual Review of Medicine Annual Reviews

Treatment of Testicular Cancer

Annual Review of Medicine , Volume 26 (1) – Feb 1, 1975

Loading next page...
 
/lp/annual-reviews/treatment-of-testicular-cancer-ucfSc1GQPj

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
Annual Reviews
Copyright
Copyright 1975 Annual Reviews. All rights reserved
Subject
Review Articles
ISSN
0066-4219
eISSN
1545-326X
DOI
10.1146/annurev.me.26.020175.001315
pmid
1096761
Publisher site
See Article on Publisher Site

Abstract

Donald 1 Twito. MD. and B. J. Kennedy. MD. Section of Medical Oncology, Department of Medicine, University of Minnesota School of Medicine, Minneapolis, Minnesota 55455 Carcinoma of the testis is one of the most common forms of lethal malignancy encountered in males IS to 40 years of age (Table 1). The average annual age­ adjusted incidence rate for all races is 3.1 per 100,000 males (1). Although occurring at all ages, it ranks first in incidence rate in males 20 to 34 years of age and accounts for 11.4% of all cancer deaths in the 25-34 age group (2). Approximately 1 % of all malignant tumors in males originate in the testis, accounting for 0.6% of all fatal tumors in males (2). The probability at birth of developing cancer of the testis is 0.16% compared to 5.5% for female breast cancer and 2.5% for lung cancer (2). It is nearly three times more common in whites than non-whites. Cancer of the testis has a significant impact on the social, economic, and emo­ tional status of this young population. There is no doubt that the prevalence of this type of cancer has been underemphasized and the public uninformed. The

Journal

Annual Review of MedicineAnnual Reviews

Published: Feb 1, 1975

There are no references for this article.